Systemic Embolism

A next-generation device for closure of the left atrial appendage to prevent thrombus embolization in patients with nonvalvular atrial fibrillation met its safety and efficacy goals, according to the results of the PINNACLE FLX study.

Among patients with atrial fibrillation, changes in quality of life affected risk for congestive HF, CV death and all-cause mortality, but changes in AF symptoms did not, according to new findings.

In a retrospective cohort study, patients with atrial fibrillation who were treated with apixaban experienced lower incidence of ischemic stroke, systemic embolism and bleeding compared with patients who received rivaroxaban.

Healio and Cardiology Today present the most-read articles on arrhythmia disorders published in 2019. In no particular order, Healio readers were most interested in results of the Apple Heart Study, the impact of wearable technologies on cardiology care, a Commentary that tackles the recent decline in the number of cardiology fellows who have chosen to pursue advanced training in cardiac electrophysiology and more.

Rates of stroke at 4 years were low for patients with nonvalvular atrial fibrillation who underwent left atrial appendage, or LAA, closure with an FDA-approved device, according to new registry data.

The FDA announced it approved two applications for the first generic versions of apixaban tablets to reduce risk for stroke and systemic embolism in patients with nonvalvular atrial fibrillation.